(24/7 MARKET NEWS) – Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) announced, this morning, that its partner’s, EMC Pharma, Microcyn Rx products received a Distribution and Pricing Agreement (DAPA) for distribution by the Defense Logistics Agency (DLA).
Sonoma Pharmaceuticals is trading at $1.71, 51-cents higher (+42.5%), on volume of 960 thousand shares traded.
Its 52-week range is $1.00 to $4.25. It’s already blown through several resistance levels and its next key inflection points are $1.76 and $2.25. If can break through the $2.25 resistance level, on strong volume, it could try to challenge its August trading levels.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.